Febuxostat Formyl Hydroxy Ethyl Ester CAS 161798-03-4 Purità > 99.0% (HPLC) Fabbrika Intermedja ta' Febuxostat
Ruifu Chemical Supply Febuxostat Intermedji Relatati:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Isem Kimiku | Etil 2-(3-Formil-4-Isobutossifenil)-4-Methylthiazole-5-Carboxylate |
Sinonimi | Febuxostat Formyl Hydroxy Ethyl Ester;Febuxostat Impurità 2;Febuxostat Intermedju 4 |
Numru CAS | 161798-03-4 |
Numru tal-KAT | RF-PI1856 |
Status tal-istokk | Fil-Ħażna, Skala ta' Produzzjoni Sa Tunnellati |
Formula Molekulari | C18H21NO4S |
Piż Molekulari | 347.43 |
Densità | 1.183 |
Brand | Ruifu Kimika |
Oġġett | Speċifikazzjonijiet |
Dehra | Trab jew Kristalli Isfar ċar għal Isfar |
Purità / Metodu ta 'Analiżi | >99.0% (HPLC) |
Kontenut tal-Ilma (KF) | <0.50% |
Residwu mat-Tqabbid | <0.50% |
Impuritajiet Totali | <1.00% |
Spettru 1H NMR | Konsistenti mal-Istruttura |
Standard tat-Test | Standard tal-Intrapriża |
Użu | Intermedju ta' Febuxostat (CAS: 144060-53-7) |
Pakkett: Flixkun, borża tal-fojl tal-aluminju, 25kg/Drum tal-Kartun, jew skont il-ħtieġa tal-klijent
Kundizzjoni tal-Ħżin:Aħżen f'kontenituri ssiġillati f'post frisk u niexef;Ipproteġi mid-dawl u l-umdità
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161798-03-4) huwa intermedju jew impurità ta 'Febuxostat (CAS: 144060-53-7).Febuxostat huwa inibitur ta 'xanthine oxidase ta' ġenerazzjoni ġdida żviluppat minn Tejin Co. (Ġappun,) użat klinikament għal trattament fit-tul ta 'hyperuicemia (gotta,) inibitur selettiv mhux purine ġdid u effettiv ħafna ta' xanthine oxidase.Mhux rakkomandat għal pazjenti tal-gotta mingħajr iperuriċemija.